Literature DB >> 12649091

Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease.

Gunilla Nordin Fredrikson1, Bo Hedblad, Göran Berglund, Ragnar Alm, Mikko Ares, Bojan Cercek, Kuang-Yuh Chyu, Prediman K Shah, Jan Nilsson.   

Abstract

OBJECTIVE: Atherosclerosis is associated with an immune response against oxidized LDL, which modulates the progression of the disease process. METHODS AND
RESULTS: Using a library of polypeptides covering the complete sequence of apoB-100, the only major protein of LDL, we have identified over 100 different human antibodies reacting against aldehyde-modified apoB-100 sequences. IgM antibody titer levels decreased with age and were associated with the intima-media thickness of the carotid artery in subjects younger than 60 years. There were also inverse associations between IgM levels and oxidized LDL in plasma. In prospective clinical studies, antibody levels against several aldehyde-modified apoB-100 sites were associated with cardiovascular disease in this age group. Whether this immune response is adaptive (protective) or maladaptive (causal) in atherosclerosis requires further investigation.
CONCLUSIONS: We have characterized a large number of epitopes within the apoB-100 component of oxidized LDL that provoke an immune response in humans. These findings will make it possible to study the role of immune responses against specific sites in oxidized LDL and to determine whether these immune responses influence the risk for future cardiac events.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649091     DOI: 10.1161/01.ATV.0000067935.02679.B0

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  51 in total

Review 1.  Vaccines for cholesterol management.

Authors:  Charles W Rittershaus
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

Review 2.  The immune system in atherosclerosis.

Authors:  Göran K Hansson; Andreas Hermansson
Journal:  Nat Immunol       Date:  2011-03       Impact factor: 25.606

Review 3.  Immunomodulation of vascular diseases: atherosclerosis and autoimmunity.

Authors:  G-P Shi
Journal:  Eur J Vasc Endovasc Surg       Date:  2010-02-25       Impact factor: 7.069

Review 4.  Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases.

Authors:  Kuang-Yuh Chyu; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 5.  Vaccine against arteriosclerosis: an update.

Authors:  Kuang-Yuh Chyu; Paul C Dimayuga; Prediman K Shah
Journal:  Ther Adv Vaccines       Date:  2017-02-01

Review 6.  Vaccination against atherosclerosis.

Authors:  Kouji Kobiyama; Ryosuke Saigusa; Klaus Ley
Journal:  Curr Opin Immunol       Date:  2019-03-29       Impact factor: 7.486

Review 7.  Vaccination to modulate atherosclerosis.

Authors:  Takayuki Kimura; Kevin Tse; Alessandro Sette; Klaus Ley
Journal:  Autoimmunity       Date:  2015-02-16       Impact factor: 2.815

8.  Model IgG monoclonal autoantibody-anti-idiotype pair for dissecting the humoral immune response to oxidized low density lipoprotein.

Authors:  Shang-Hung Chang; Michael Johns; Joseph J Boyle; Ellen McConnell; Paul A Kirkham; Colin Bicknell; M Zahoor-ul-Hassan Dogar; Robert J Edwards; Oliver Gale-Grant; Ramzi Khamis; Kurrun V V Ramkhelawon; Dorian O Haskard
Journal:  Hybridoma (Larchmt)       Date:  2012-04

Review 9.  T cells in atherosclerosis.

Authors:  Kevin Tse; Harley Tse; John Sidney; Alex Sette; Klaus Ley
Journal:  Int Immunol       Date:  2013-11       Impact factor: 4.823

10.  Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis.

Authors:  Andreas Hermansson; Daniel F J Ketelhuth; Daniela Strodthoff; Marion Wurm; Emil M Hansson; Antonino Nicoletti; Gabrielle Paulsson-Berne; Göran K Hansson
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.